Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Feasibility of a Minimally Invasive Image-Guided Surgery System for Hepatic Procedures

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Pathfinder Therapeutics
ClinicalTrials.gov Identifier:
NCT01237990
First received: November 8, 2010
Last updated: January 19, 2012
Last verified: January 2012

November 8, 2010
January 19, 2012
August 2010
October 2011   (final data collection date for primary outcome measure)
The number of accepted liver registrations associated with laparoscopically acquired surface data compared with the number of accepted liver registrations associated with open liver acquired surface data. [ Time Frame: 30 Days ] [ Designated as safety issue: No ]
Subjects are followed for the study 30days (+/- 14 days) and are considered to have completed the study following this 30 day follow-up visit.
Same as current
Complete list of historical versions of study NCT01237990 on ClinicalTrials.gov Archive Site
Comparison of registration errors from the full and half sufflation pressures to determine an impact of insufflation pressure on registration accuracy. [ Time Frame: 30 Days ] [ Designated as safety issue: No ]
Subjects are followed for the study up to 30days (+/- 14 days) and are considered to have completed the study following this 30 day follow-up visit.
Same as current
Not Provided
Not Provided
 
Feasibility of a Minimally Invasive Image-Guided Surgery System for Hepatic Procedures
Feasibility of a Minimally Invasive Image-Guided Surgery System for Hepatic Procedures

This study was designed to confirm that the surgeon is able to perform surface registration of standard liver features used as landmarks during a scheduled laparoscopic liver procedure. Additionally, registrations will be obtained with full insufflation pressure and with half insufflation pressure during the laparoscopic procedure. Under the presence of both insufflation pressures, the surface of the liver will be manually swabbed with the study tracked laparoscopic probe with landmarks noted during data collection. After registration of the liver is obtained, the registration points obtained during this procedure will be evaluated by the surgeon by moving the tracked laparoscopic probe over the liver surface and evaluating the location of the tracked laparoscopic probe displayed on the guidance system 3D image. The surgeon will accept or reject the registration accuracy. Upon completion of the scheduled laparoscopic procedure, the subject will then undergo the open procedure scheduled for the surgical case. An open liver registration will be obtained with manual swabbing of the liver using the study tracked probe and will be accepted or rejected by the surgeon using the process described in the laparoscopic procedure.

In the event that the disease is determined to be too great for surgical repair during the laparoscopic staging procedure, only minimally invasive liver surface data will be acquired and the patient will not be included in the overall study population.

The Pathfinder System used during this study is used for data collection purposes only and is not used during the surgical procedure as an image guided system.

Preoperative CT scans, obtained as standard of care, will be used to generate the image guided liver system 3D liver surface images used during the study.

During the laparoscopic procedure, the Pathfinder device will be inserted through the standard laparoscopic ports (5mm or 10mm) being used for the staging procedure.

For the purposes of the study, subjects will be enrolled following the inclusion/exclusion criteria below:

Inclusion:

  1. Written informed consent must be obtained.
  2. Patients enrolled must be undergoing a staging laparoscopy for with the intention for conversion to laparotomy.
  3. Patient must be 18 years of age or older.
  4. Women of childbearing age without documented evidence of menopause or sterility must have a negative serum or urine pregnancy test at the time of screening.

Exclusion:

  1. Any condition which, in the judgement of the clinical investigator or his designee, might increase the risk to the subject or decrease the chance of obtaining satisfactory data to achieve the objectives of the study.
  2. Patients that have a condition rendering them unable to understand the nature, scope and possible consequences of this study and therefore unable to give proper consent.
  3. Patients with Cirrhosis of the liver classified as Child-Pugh B or C.
  4. Patients undergoing liver surgery for the purpose of receiving a liver transplant.
  5. Patients with established renal insufficiency (defined as creatinine greater than 2.5 mg/dl), or a condition that requires hemodialysis.

A total study population will include 20 subjects that complete both the laparoscopic and open liver procedures scheduled.

Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Any subject with liver cancer scheduled for a laparoscopic staging and open liver resection procedure.

Liver Cancer
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
20
October 2011
October 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Clinical Diagnosis of Liver Cancer
  • Scheduled for liver surgery

Exclusion Criteria:

  • Receiving a liver transplant
  • Kidney failure or dialysis
  • Unable to consent
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01237990
PTI-LC-2009-01
Yes
Pathfinder Therapeutics
Pathfinder Therapeutics
Not Provided
Principal Investigator: William Jarnagin, M.D. Memorial Sloan-Kettering Cancer Center
Pathfinder Therapeutics
January 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP